Cochrane Review Group

Gut

172 systematic reviews in Gut ask 2,395 questions. 17.5% have no studies to answer them, 34.3% rest on very low certainty evidence and 20.6% reach moderate or high certainty.

Reviews

172

Questions

2,395

current versions

No studies

17.5%

Moderate or high

20.6%

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Gut

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Infliximab vs purine analogues Loss of clinical response · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Withdrawal due to adverse events · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs purine analogues Serious adverse events (at 2 years) · Crohn's disease patients (in remission at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.79 [0.37, 1.68]	1 study · 140 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Clinical relapse (at 22 weeks, CDAI > 150) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 1.01 [0.65, 1.57]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.94 [0.7, 1.25]	1 study · 53 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Withdrawal due to adverse events (at 30 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.77 [0.3, 1.97]	1 study · 53 participants	Very low
Infliximab vs placebo Loss of clinical response (at 32 weeks, less than 70 points in CDAI change) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.59 [0.37, 0.96]	1 study · 73 participants	Very low
Subcutaneous CT‐P13 and purine analogues vs intravenous CT‐P13 and purine analogues Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	no estimate extracted	NR	No studies
Infliximab vs adalimumab Loss of clinical response (at 56 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.68 [0.29, 1.59]	1 study · 73 participants	Very low
Infliximab vs adalimumab Withdrawal due to adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.1 [0.01, 0.72]	1 study · 73 participants	Very low
Infliximab vs adalimumab Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline) Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane	RR 0.09 [0.01, 1.54]	1 study · 73 participants	Very low

Reviews 172

Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy

Dong, Z, Xu, J, et al. · Cochrane Database of Systematic Reviews · 2016

Gut

Thinnest evidence

Reviews 172

Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy

Sequential versus standard triple first‐line therapy for Helicobacter pylori eradication

Osmotic and stimulant laxatives for the management of childhood constipation

Periodontal therapy as adjunctive treatment for gastric Helicobacter pylori infection

Pancreatic duct guidewire placement for biliary cannulation for the prevention of post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis

Transcutaneous electrical stimulation (TES) for treatment of constipation in children

Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery

Interventions for necrotising pancreatitis

Laparoscopic versus open gastrectomy for gastric cancer

Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer

Laparoscopic versus open distal pancreatectomy for pancreatic cancer

Management strategies for pancreatic pseudocysts

Molecular‐targeted first‐line therapy for advanced gastric cancer

Non‐surgical versus surgical treatment for oesophageal cancer

Duodenum‐preserving pancreatic resection versus pancreaticoduodenectomy for chronic pancreatitis

Pregabalin for decreasing pancreatic pain in chronic pancreatitis

Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease

Budesonide for induction of remission in Crohn's disease

Preoperative chemotherapy for resectable thoracic esophageal cancer

Extent of lymph node dissection for adenocarcinoma of the stomach

Laparoscopic fundoplication surgery versus medical management for gastro‐oesophageal reflux disease (GORD) in adults

Metoclopramide for post‐pyloric placement of naso‐enteral feeding tubes

Unfractionated or low‐molecular weight heparin for induction of remission in ulcerative colitis

Type I interferons for induction of remission in ulcerative colitis

Methotrexate for maintenance of remission in ulcerative colitis